Decade of Vaccines Collaboration

in page functions

Working to realise a 10-year vision to extend the full benefits of immunisation to all people regardless of where they live. 
 

Decade of Vaccines Collaboration

In 2010, the global health community declared the next ten years to be the Decade of Vaccines with a vision to extend the full benefits of immunisation to all people, regardless of where they are born, who they are, or where they live.

The Decade of Vaccines (DoV) Collaboration is working to realise the vision by developing a global vaccine action plan (GVAP) and coordinating with organisations such as the Vaccine Alliance to enhance worldwide participation.

Gavi serves on the Leadership Council of the DoV Collaboration and provides critical expertise and leadership as part of the organisation’s Steering Committee.

Global Vaccine Action Plan

The development of the GVAP is a unique effort with an unprecedented emphasis on gathering country-led input and ownership. The end goal is to create a transformational plan that will stimulate the discovery, development and delivery of lifesaving vaccines.

An essential component of the creation of the GVAP is the participation of key stakeholders involved in immunisation, health, and development to provide input through a global consultation process, including an online consultation from January 16 – February 1, 2012. To learn more about the DoV Collaboration and take part in the consultation process, please visit dovcollaboration.org.

Vaccines Work: Key Facts and Figures

  • Beyond preventing more than 100 million cases of illness and averting 3.7 million deaths in young children over the next ten years, immunizing children with three crucial vaccines against pneumonia, diarrhea and meningitis would hold major economic benefits for both families and governments.
  • Rolling out childhood immunizations against Hib, pneumococcal and rotavirus diseases in the world’s 73 poorest countries over the next decade would result in an estimated $63 billion in treatment and productivity savings.
  • Averting short-term costs of disease treatment saves $1.4 billion and avoiding the lost wages of caretakers saves $313 million, while averting the long term economic costs of lost productivity due to disability and death may add savings of $61 billion to these economies in the long term.
  • The ability to avert 3.7 million deaths by using pneumococcal, Hib and rotavirus vaccines has an estimated value of $115 billion for those in at-risk countries.

More on this topic

close icon

modal window here